

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **January 10, 2026**

**Kiniksa Pharmaceuticals International, plc**

(Exact name of Registrant as Specified in Its Charter)

**England and Wales**  
(State or other jurisdiction of  
incorporation or organization)

**001-730430**  
(Commission  
File Number)

**98-1795578**  
(I.R.S. Employer  
Identification No.)

**105 Piccadilly, Second Floor  
London, W1J 7NJ  
England, United Kingdom  
(781) 431-9100**

(Address, zip code and telephone number, including area code of principal executive offices)

**Kiniksa Pharmaceuticals Corp.  
100 Hayden Avenue  
Lexington, MA, 02421  
(781) 431-9100**

(Address, zip code and telephone number, including area code of agent for service)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of each exchange on which registered</u>
Class A Ordinary Shares \$0.000273235 nominal value	KNSA	The Nasdaq Stock Market LLC (Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

Effective January 10, 2026, the Board of Directors of Kiniksa Pharmaceuticals International, plc (the “Company”) appointed Ross Moat to the position of Chief Operating Officer and principal operating officer. Following the appointment, Mr. Moat will continue to oversee the Company’s commercial operations, in addition to functional operations under the Chief Operating Officer title. There were no changes to Mr. Moat’s compensation arrangements in connection with this appointment.

In addition, effective January 10, 2026, the Company’s Board of Directors appointed Eben Tessari to the position of Chief Strategy Officer. Mr. Tessari will continue to oversee the Company’s strategic, business development and technical operations, in addition to responsibility for the Company’s artificial intelligence initiatives. There were no changes to Mr. Tessari’s compensation arrangements in connection with this appointment.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC

Date: January 14, 2026

By: /s/ Douglas Barry

\_\_\_\_\_  
Douglas Barry

Senior Vice President, Chief Legal Officer

---